Orocidin QR-01 Shows a Good Safety Profile in Preclinical Toxicity Study
Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Orocidin A/S, a subsidiary of Nordicus Partners (OTCQB: NORD), has successfully completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis. The study involved dosing hamsters over a 2-week period with concentrations 5-8 times higher than planned for the upcoming pilot efficacy study in patients.
The results demonstrated high drug tolerance in all test subjects, with no adverse reactions or irritation at the buccal application site. Notably, necroscopic cross examination revealed no tissue changes. This successful completion marks a significant milestone for Orocidin, paving the way for the upcoming pivotal eight-week toxicity study.
Positive
- Successful completion of initial toxicity study for QR-01
- No adverse reactions or safety concerns observed at 5-8x planned dosage
- Clear path forward to eight-week pivotal toxicity study
Negative
- None.
Details
News Market Reaction – NORD
The recorded move for NORD in the trading session of this news was +23.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEVERLY HILLS, California, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orocidin A/S (“Orocidin”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, has successively completed its first toxicity study for QR-01, a novel treatment for aggressive periodontitis.
In the study, Orocidin dosed hamsters over a 2-week period with a concentration 5-8 times higher than the planned dose for the upcoming pilot efficacy study in patients.
“We are pleased to report that all animals exhibited high tolerance to the drug, with no adverse reactions and irritation at the buccal application site. No significant side effects were observed and more importantly, the necroscopic cross examination showed no changes in tissues.” said Allan Wehnert, CEO & Founder of Orocidin.
The successful completion of this study marks an important milestone for Orocidin, providing the foundation for the upcoming pivotal eight-week toxicity study.
For further information, contact:
Mr. Henrik Rouf
Chief Executive Officer
hr@nordicuspartners.com
Tel +1 310 666 0750
Investor Relations
Jonathan Paterson
Harbor Access Investor Relations
Jonathan.Paterson@Harbor-Access.com
Tel +1 475 477 9401
About Orocidin
Orocidin’s mission is to develop the preferred treatment against aggressive periodontitis. Our innovative therapeutic agent, QR-01, distinguishes itself through its unique ability to provide treatment of both inflammation and bacterial infection.
About Nordicus Partners Corporation
Nordicus Partners Corporation is the only U.S. publicly traded business accelerator and holding company for Nordic life sciences companies. Leveraging decades of combined management experience in domestic and global corporate sectors, Nordicus excels in corporate finance activities including business and market development, growth strategies, talent acquisition, partnership building, capital raising, and facilitating company acquisitions and sales. In 2024, Nordicus acquired
Cautionary Note Regarding Forward-Looking Statements:
This press release may contain forward-looking statements that involve substantial risks and uncertainties. You can identify these statements by the use of forward-looking terminology such as “may,” “will,” “should,” “expect,” “anticipate,” “project,” “estimate,” “intend,” “continue” or “believe” or the negatives thereof or other variations thereon or comparable terminology. You should read statements that contain these words carefully because they discuss our plans, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. We believe that it is important to communicate our future expectations to our investors. There may be events in the future, however, that we are not able to predict accurately or control. Any forward-looking statement made by us in this press release speaks only as of the date on which we make it. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.